<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525288</url>
  </required_header>
  <id_info>
    <org_study_id>17.229</org_study_id>
    <secondary_id>PERA GU17.1</secondary_id>
    <nct_id>NCT03525288</nct_id>
  </id_info>
  <brief_title>PSMA-PET Guided Radiotherapy</brief_title>
  <acronym>PSMA-PETgRT</acronym>
  <official_title>PSMA-PET Guided Radiotherapy in Patients With High-Risk, Recurrent, or Oligometastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Progenics Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PSMA PET/CT has demonstrated higher sensitivity in detecting metastases than current imaging&#xD;
      standard of care (CT and bone scan). [18F]DCFPyL is a promising high-sensitivity second&#xD;
      generation PSMA-targeted urea-based PET probe. The hypothesis is that definitive radiotherapy&#xD;
      (RT) informed by PSMA-PET findings will lead to improved cancer control outcomes compared to&#xD;
      RT guided by conventional staging only. This study utilizes cmRCT design in companion to PERA&#xD;
      (Partnership initiative for the Evaluation of technological innovation in Radiotherapy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are randomly selected from a standard-care cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time to failure event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute and delayed toxicities</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of Attributable Gr2+ toxicities (CTCAE v4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of failure</measure>
    <time_frame>5 years</time_frame>
    <description>Event rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Event rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Qol measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection yield of PSMA PET imaging</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of new lesions identified on imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PSMA-PETgRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient's receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PSMA -PET/CT simulation</intervention_name>
    <description>PET/CT simulation.&#xD;
If no additional lesions detected: RT as planned per standard care.&#xD;
If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.&#xD;
If PSMA-PET/CT imaging consistent with widely metastatic disease (&gt;5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged.</description>
    <arm_group_label>PSMA-PETgRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard-care simulation</intervention_name>
    <description>No PSMA-PET/CT as part of RT treatment planning.</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Enrolled in PERA (CHUM CER 17.0.32) and consented to contact for investigational&#xD;
             trials.&#xD;
&#xD;
          2. Histological diagnosis of prostate cancer planned for curative-intent radiotherapy.&#xD;
&#xD;
          3. ECOG 0-1&#xD;
&#xD;
          4. Charlson Cormobidity Index ≤ 4&#xD;
&#xD;
          5. High-risk of distant metastases as defined by any of:&#xD;
&#xD;
               1. Oligometastases (≤5) (regional or distant) identified on conventional staging,&#xD;
                  with ≤ 3 metastasis in any non-bone organ. For a spine metastasis, direct&#xD;
                  involvement of adjacent spinal segments would still be considered as &quot;one&quot;&#xD;
                  tumour. For nodal metastases, more than one involved lymph node in the same&#xD;
                  ipsilateral nodal region/chain would still count as &quot;one&quot; tumour. Defined nodal&#xD;
                  regions for this protocol include inguinal, external iliac, internal iliac,&#xD;
                  common iliac, retroperitoneal, hilar/mediastinal, anterior cervical, posterior&#xD;
                  cervical, and axillary. Metastases in all other organs that are within 1cm of&#xD;
                  each other will be considered as &quot;one&quot; tumour.&#xD;
&#xD;
               2. Subjects with newly diagnosed high-risk (NCCN) localized prostate cancer and&#xD;
                  CAPRA score 6-10.&#xD;
&#xD;
               3. Subjects with a prior history of treated prostate cancer (RP or RT), and&#xD;
                  biochemical failure (Phoenix-RT or&gt;0.2ng/ml-RP)&#xD;
&#xD;
          6. Standard staging (bone scan, CT pelvis) within 12 weeks of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior androgen deprivation therapy terminated &lt; 12 months prior to enrollment.&#xD;
&#xD;
          2. Prior or planned PET scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CSSSL - Cité de la Santé Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

